Pay in 4 interest-free payments of $6.83 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
For PA-NOT-MET denials, file a level-1 internal appeal within 180 days
Bottom line The December 2024 approval of generic Victoza (liraglutide) represents a significant milestone in making GLP-1 medications more accessible and affordable for people looking to manage their type 2 diabetes and lose weight
Br Med J 1993;306:1645-8
The authors declare that this article received funding from Novo Nordisk
(Found online July 11, 2024) Sounding alarms on safety The FDA has issued myriad public warnings about compounded semaglutide and misbranded, unapproved counterfeit versions
The landscape changed dramatically in 2025
US$ 21.63
:max_bytes(150000):strip_icc()/GLP-1-Users-Disrupting-Food-Industry-FT-DGTL0126-ef7c3fcc00e8441195e909393d0d7a9c.jpg)
US$ 24.03
US$ 28.73
